V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004757 | 10002995 | 1.78 | 100 | Neo-adjuvant (N) | null | 2016-11-18 | Mitomycin Intravesical | N | N | 10545056 | FLAIR TRIAL |
| 10004758 | 10002995 | 1.67 | 68.4 | null | null | 2018-03-30 | COMPLEMENT TRIAL | N | null | 10545056 | COMPLEMENT TRIAL |
| 10004759 | 10002995 | 1.62 | 101.45 | Adjuvant (A) | null | 2017-01-26 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | null | null | 10545056 | MPV |
| 10004760 | 10002996 | 1.72 | 63.2 | Palliative (P) | 2018-01-14 | 2018-01-21 | Pazopanib | N | N | 10545099 | SORAFENIB |
| 10004761 | 10002997 | 1.74 | 85 | Palliative (P) | 2015-12-13 | 2015-12-23 | CARBOPLATIN + RT | N | N | 10545106 | REMODL TRIAL |
| 10004762 | 10006713 | 1.74 | 98.3 | Neo-adjuvant (N) | 2016-11-26 | 2016-11-28 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 10545232 | CHLVPP |
| 10004763 | 10002998 | 1.74 | 0 | Palliative (P) | 2016-07-20 | 2016-08-02 | CISPLATIN + GEMCITABINE + RITUXIMAB | N | N | 10545258 | DOXORUBICIN |
| 10004764 | 10002999 | null | 124.2 | Palliative (P) | 2016-02-04 | 2016-02-27 | Cyclophosphamide + Docetaxel | 2 | N | 10545272 | CARBOPLATIN + PACLITAXEL + RT |
| 10004765 | 10002999 | 1.53 | 70 | null | 2015-05-20 | 2015-12-01 | Erlotinib | 2 | N | 10545272 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004766 | 10003000 | 1.64 | 78 | Neo-adjuvant (N) | 2016-03-02 | 2016-03-07 | Trastuzumab Subcutaneous | 2 | N | 10545437 | CAPECITABINE + CISPLATIN + RT |
| 10004767 | 10003001 | null | null | Palliative (P) | 2018-03-13 | 2018-03-30 | Sorafenib | 02 | N | 10545462 | FCR |
| 10004768 | 10003002 | 1.69 | 60.5 | Palliative (P) | 2017-06-02 | 2017-06-03 | Cisplatin + Docetaxel +Fluorouracil | N | N | 10545515 | CARBOPLATIN + RT |
| 10004769 | 10003003 | 1.69 | 64 | Neo-adjuvant (N) | null | 2017-08-04 | MELPHALAN | N | null | 10545551 | CISPLATIN + ETOPOSIDE + RT |
| 10004770 | 10003004 | null | 59.1 | Palliative (P) | 2016-09-11 | 2016-09-19 | Folfirinox | null | N | 10545578 | NOT MATCHED |
| 10004771 | 10003005 | 1.8 | 99.3 | Neo-adjuvant (N) | 2018-01-19 | 2018-02-12 | DA 3 + 10 | N | N | 10545602 | FLUOROURACIL + MITOMYCIN |
| 10004772 | 10003005 | 1.74 | 108 | Palliative (P) | null | 2017-06-20 | Gefitinib: 1 to 2 & 4 onwards | N | N | 10545602 | CAPECITABINE + MITOMYCIN + RT |
| 10004773 | 10003005 | 0 | 85 | Palliative (P) | 2014-10-20 | 2014-10-28 | Capecitabine (14 day) + Irinotecan | N | N | 10545602 | IDELALISIB + RITUXIMAB |
| 10004774 | 10003006 | null | 98.7 | null | null | 2016-05-06 | MPV (cycle 1-4) | 02 | N | 10545634 | GEFITINIB |
| 10004775 | 10003007 | 1.64 | 0 | Disease modification (D) | 2018-10-27 | 2018-10-31 | MYELOMA XI TRIAL | N | N | 10545670 | BENDAMUSTINE |
| 10004776 | 10003008 | 1.65 | 63 | Palliative (P) | 2015-05-24 | 2015-05-31 | CAPECITABINE + MITOMYCIN + RT | 2 | N | 10545673 | PACLITAXEL + TRASTUZUMAB |
| 10004777 | 10003008 | 1.82 | 90.5 | Not known (9) | 2016-10-22 | 2016-11-04 | CETUXIMAB + RT | N | N | 10545673 | BEVACIZUMAB + CAPECITABINE |
| 10004778 | 10003008 | 0 | 79.8 | Curative (C) | 2015-08-16 | 2015-09-11 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 10545673 | ABVD R |
| 10004779 | 10003009 | null | 83.6 | Palliative (P) | 2018-09-03 | 2018-09-05 | CISPLATIN + VINORELBINE + RT | N | N | 10545732 | DARATUMUMAB |
| 10004780 | 10003009 | 1.75 | 0 | Curative (C) | 2018-12-28 | 2018-12-28 | MELPHALAN | 02 | N | 10545732 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004781 | 10008219 | null | 110 | Not known (9) | 2015-09-21 | 2015-09-21 | Bendamustine +/- Prednisolone | N | N | 10545782 | MPV |
| 10004782 | 10003010 | 1.74 | 67.199 | null | 2013-08-04 | 2013-08-09 | Pazopanib | N | null | 10545835 | CAPECITABINE + CARBOPLATIN |
| 10004783 | 10003010 | 1.79 | 82 | Palliative (P) | 2017-11-24 | 2017-11-25 | FLUOROURACIL + MITOMYCIN | N | N | 10545835 | PAZOPANIB |
| 10004784 | 10003011 | 0 | 55 | Palliative (P) | 2018-03-30 | 2018-04-10 | RIALTO TRIAL | 02 | N | 10545863 | CYCLOPHOSPHAMIDE + DOCETAXEL |
| 10004785 | 10003011 | 1.65 | 83.6 | Palliative (P) | 2018-06-06 | 2018-06-15 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | N | N | 10545863 | TRASTUZUMAB |
| 10004786 | 10003011 | 1.86 | 77.6 | Palliative (P) | 2018-01-06 | 2018-01-28 | DABRAFENIB + TRAMETINIB | N | N | 10545863 | CETUXIMAB |
| 10004787 | 10003011 | 1.68 | 67.9 | Curative (C) | 2017-07-31 | 2017-08-12 | Ralitrexed | N | null | 10545863 | ERLOTINIB |
| 10004788 | 10003011 | null | 78 | Palliative (P) | 2017-07-15 | 2017-08-03 | CISPLATIN + FLUOROURACIL + RT | N | N | 10545863 | RUXOLITINIB |
| 10004789 | 10003011 | 1.83 | null | Curative (C) | 2017-10-22 | 2017-11-02 | Cape+Cisplatin+Trastuzumab Load | N | N | 10545863 | CHLORAMBUCIL + RITUXIMAB |
| 10004790 | 10003012 | null | 80.1 | Disease modification (D) | 2014-01-21 | 2014-01-24 | RCEOP | 2 | N | 10546066 | BORTEZOMIB + THALIDOMIDE |
| 10004791 | 10006720 | 1.76 | 73.4 | Palliative (P) | 2014-05-18 | 2014-06-15 | Cisplatin + Docetaxel | N | N | 10546115 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004792 | 10006720 | 1.65 | 89.3 | Adjuvant (A) | 2014-08-29 | 2014-09-01 | Bendamustine +/- Prednisolone | 02 | N | 10546115 | BEP |
| 10004793 | 10006720 | 1.78 | null | Palliative (P) | 2017-11-16 | 2017-11-17 | FCR | 02 | null | 10546115 | CARBOPLATIN + RT |
| 10004794 | 10006720 | 1.73 | null | Curative (C) | 2017-12-04 | 2018-01-26 | EP | N | N | 10546115 | QUASAR 2 TRIAL |
| 10004795 | 10006720 | 1.7 | null | Palliative (P) | 2018-03-31 | 2018-03-31 | Cetuximab + Radiotherapy Load | N | N | 10546115 | CHLORAMBUCIL + RITUXIMAB |
| 10004796 | 10006720 | 1.67 | 88.2 | Palliative (P) | 2017-04-17 | 2017-05-03 | LENALIDOMIDE | 2 | N | 10546115 | CETUXIMAB |
| 10004797 | 10006720 | 1.77 | 0 | Not known (9) | 2013-06-27 | 2013-06-27 | R GDP + DEXAMETHASONE | N | N | 10546115 | BRENTUXIMAB |
| 10004798 | 10006720 | 1.73 | null | Palliative (P) | 2014-10-31 | 2014-11-09 | CAPECITABINE + MITOMYCIN + RT | 2 | null | 10546115 | LOMUSTINE |
| 10004799 | 10006720 | 1.7 | null | Disease modification (D) | 2017-09-09 | 2017-10-01 | Bortezomib + MELPHALAN | N | N | 10546115 | TCH |
| 10004800 | 10003013 | null | 90.5 | Palliative (P) | 2018-09-01 | 2018-09-07 | MYELOMA XI TRIAL | 02 | N | 10546510 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10004801 | 10003014 | 1.56 | 107.9 | Curative (C) | 2016-09-10 | 2016-10-04 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10546526 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10004802 | 10003014 | null | null | Curative (C) | 2015-01-20 | 2015-01-31 | RUXOLITINIB | 02 | Y | 10546526 | BORTEZOMIB + THALIDOMIDE |
| 10004803 | 10003014 | 1.62 | 73.4 | Palliative (P) | 2018-05-09 | 2018-05-10 | Doxorubicin chemoembolisation | 02 | N | 10546526 | IBRUTINIB |
| 10004804 | 10003015 | 1.83 | 76 | Palliative (P) | 2018-09-16 | 2018-09-16 | Vemurafenib | Y | N | 10546581 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB |
| 10004805 | 10003015 | 0 | 73.2 | Disease modification (D) | 2014-11-24 | 2014-11-24 | DABRAFENIB + TRAMETINIB | 02 | N | 10546581 | PEMETREXED |
| 10004806 | 10003016 | 1.79 | 72.4 | Palliative (P) | 2018-07-24 | 2018-07-26 | IPILIMUMAB + NIVOLUMAB | N | N | 10546601 | CHLORAMBUCIL + RITUXIMAB |